Heparin in the Treatment of Critically Ill Patients on the ICU

  • M. Levi
  • A. Cornelie de Pont
  • E. de Jonge
Conference paper

Abstract

Not all physicians will realize that, when they inject 1 ml of heparin in a patient, they in fact inject a cocktail of more than 100 different molecules. Heparin consists of a large number of glycosaminoglycans of various molecular size (4–20 kDa) (Fig. 1) that are isolated from the intestines or lungs of pig or cow [1]. Heparin is able to bind to antithrombin III, thereby more than 1000-fold potentiating the inhibitory effect of antithrombin III on coagulation factors IIa (thrombin) and Xa. Besides this anticoagulant effect, heparin (and in particular its high molecular weight constituents) may also inhibit platelet function [2]. Although the subject of some controversy in the past, heparin does not appear to exert thrombolytic activity. The weight of evidence suggests that heparin has no direct effect on clot lysis, but strongly inhibits the recurrent formation of thrombotic deposits during the process of endogenous fibrinolysis [3].

Keywords

Venous Thromboembolism Disseminate Intravascular Coagulation Unfractionated Heparin Disseminate Intravascular Coagulation Porcine Heparin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirsh J (1991) Heparin. N Engl J Med 324: 1565 - 1574CrossRefGoogle Scholar
  2. 2.
    Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114: 489S - 5105PubMedCrossRefGoogle Scholar
  3. 3.
    Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, ten Cate JW (1996) Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 93: 153 - 160PubMedCrossRefGoogle Scholar
  4. 4.
    Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337: 688 - 698PubMedCrossRefGoogle Scholar
  5. 5.
    Hirsh J (1993) Low molecular weight heparin. Thromb Haemost 70: 204 - 207PubMedGoogle Scholar
  6. 6.
    Bijsterveld NR, Hettiarachchi R, Peters R, Levi M, Buller HR (1999) Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 82 (suppl 1): 139 - 147PubMedGoogle Scholar
  7. 7.
    Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114: 489S - 510SPubMedCrossRefGoogle Scholar
  8. 8.
    Agnelli G, Sonaglia F (2000) Prevention of venous thromboembolism. Thromb Res 97: V49 - V62PubMedCrossRefGoogle Scholar
  9. 9.
    Geerts W, Cook D, Selby R, Etchells E (2002) Venous thromboembolism and its prevention in critical care. J Crit Care 17: 95 - 104PubMedCrossRefGoogle Scholar
  10. 10.
    Cook D, Attia J, Weaver B, McDonald E, Meade M, Crowther M (2000) Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care 15: 127 - 132PubMedCrossRefGoogle Scholar
  11. 11.
    Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161: 1268 - 1279PubMedCrossRefGoogle Scholar
  12. 12.
    Marik PE, Andrews L, Maini B (1997) The incidence of deep venous thrombosis in ICU patients. Chest 111: 661 - 664PubMedCrossRefGoogle Scholar
  13. 13.
    Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10: 448 - 450PubMedCrossRefGoogle Scholar
  14. 14.
    Samama MM, Cohen AT, Darmon JY, et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793-800Google Scholar
  15. 15.
    Geerts WH, Jay RM, Code KI, et al (1996) A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 335: 701 - 707PubMedCrossRefGoogle Scholar
  16. 16.
    ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ (1997) Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 78: 415 - 419PubMedGoogle Scholar
  17. 17.
    Dorffler-Melly J, de Jonge E, Pont AC, Meijers J, Buller HR, Levi M (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359: 849 - 850PubMedCrossRefGoogle Scholar
  18. 18.
    Mayr AJ, Dunser M, Jochberger S, et al (2002) Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 105: 201 - 204PubMedCrossRefGoogle Scholar
  19. 19.
    Ward DM (1997) The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Adv Ren Replace Ther 4: 160 - 173PubMedGoogle Scholar
  20. 20.
    Martin PY, Chevrolet JC, Suter P, Favre H (1994) Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 24: 806 - 812PubMedGoogle Scholar
  21. 21.
    Prentice CR (1985) Acquired coagulation disorders. Clin Haematol 14: 413 - 442PubMedGoogle Scholar
  22. 22.
    Lai KN, Ho K, Li M, Szeto CC (1998) Use of single dose low-molecular-weight heparin in long hemodialysis. Int J Artif Organs 21: 196 - 200PubMedGoogle Scholar
  23. 23.
    Timsit JF, Farkas JC, Boyer JM, et al (1998) Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. Chest 114: 207 - 213PubMedCrossRefGoogle Scholar
  24. 24.
    Hentschel R, Wiescholek U, von Lengerke J, Harms E, Jorch G (1999) Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis - a prospective study. Eur J Pediatr 158 (suppl 3): S126 - 5129PubMedCrossRefGoogle Scholar
  25. 25.
    Heilskov J, Kleiber C, Johnson K, Miller J (1998) A randomized trial of heparin and saline for maintaining intravenous locks in neonates. J Soc Pediatr Nurs 3: 111 - 116PubMedCrossRefGoogle Scholar
  26. 26.
    Epperson EL (1984) Efficacy of 0.9% sodium chloride injection with and without heparin for maintaining indwelling intermittent injection sites. Clin Pharm 3: 626 - 629PubMedGoogle Scholar
  27. 27.
    Hanrahan KS, Kleiber C, Berends S (2000) Saline for peripheral intravenous locks in neonates: evaluating a change in practice. Neonatal Netw 19: 19 - 24PubMedCrossRefGoogle Scholar
  28. 28.
    Randolph AG, Cook DJ, Gonzales CA, Andrew M (1998) Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. Br Med J 316: 969 - 975CrossRefGoogle Scholar
  29. 29.
    Geerts WH, Heit JA, Clagett GP, et al (2001) Prevention of venous thromboembolism. Chest 119: 132S - 175SPubMedCrossRefGoogle Scholar
  30. 30.
    Levine MN, Raskob G, Landefeld S, Kearon C (2001) Hemorrhagic complications of anticoagulant treatment. Chest 119: 1085 - 121SCrossRefGoogle Scholar
  31. 31.
    Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL (2002) The time course of platelet counts in critically ill patients. Crit Care Med 30: 753 - 6PubMedCrossRefGoogle Scholar
  32. 32.
    Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG (2002) Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 30: 1765 - 1771PubMedCrossRefGoogle Scholar
  33. 33.
    Cook DJ, Griffith LE, Walter SD, et al (2001) The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 5: 368 - 375PubMedCrossRefGoogle Scholar
  34. 34.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586 - 592PubMedCrossRefGoogle Scholar
  35. 35.
    Levi M, van Gorp E, ten Cate H (2003) Disseminated intravascular coagulation. In: Handin RI (ed) Blood: Principles and Practice of Hematology. Lippincott, Williams and Wilkins, Philadelphia (in press)Google Scholar
  36. 36.
    Little JR (1959) Purpura fulminans treated successfully with anticoagulation: report of a case. JAMA 169: 36 - 40CrossRefGoogle Scholar
  37. 37.
    Corrigan JJ Jr, Kiernat JF (1975) Effect of heparin in experimental gram-negative septicemia. J Infect Dis 131: 138 - 143PubMedCrossRefGoogle Scholar
  38. 38.
    Corrigan JJ Jr (1977) Heparin therapy in bacterial septicemia. J Pediatr 91: 695 - 700PubMedCrossRefGoogle Scholar
  39. 39.
    Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M (1993) Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation ( DIC) - a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 72: 475-500Google Scholar
  40. 40.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699 - 709PubMedCrossRefGoogle Scholar
  41. 41.
    Warren BL, Eid A, Singer P, et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869 - 1878PubMedCrossRefGoogle Scholar
  42. 42.
    Aznar J, Espana F, Estelles A, Royo M (1996) Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor - influence of the molecular weight of heparin and ionic strength. Thromb Haemost 76: 983 - 988PubMedGoogle Scholar
  43. 43.
    Friedrich U, Blom AM, Dahlback B, Villoutreix BO (2001) Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 276: 24122 - 24128PubMedCrossRefGoogle Scholar
  44. 44.
    Kelton JG (2002) Heparin-induced thrombocytopenia: an overview. Blood Rev 16: 77 - 80PubMedCrossRefGoogle Scholar
  45. 45.
    Warkentin TE, Levine MN, Hirsh J, et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330 - 1335PubMedCrossRefGoogle Scholar
  46. 46.
    Konlde BA, Bauer TL, Arepally G, et al (2001) Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg 71: 1920 - 1924CrossRefGoogle Scholar
  47. 47.
    Baglin TP (2001) Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 54: 272 - 274PubMedCrossRefGoogle Scholar
  48. 48.
    Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344: 1286 - 1292PubMedCrossRefGoogle Scholar
  49. 49.
    Ibbotson T, Perry CM (2002) Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 62: 2283 - 2314PubMedCrossRefGoogle Scholar
  50. 50.
    Lubenow N, Greinacher A (2002) Hirudin in heparin-induced thrombocytopenia. Semin Thromb Hemost 28: 431 - 438PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Levi
  • A. Cornelie de Pont
  • E. de Jonge

There are no affiliations available

Personalised recommendations